Raltitrexed/5-fluorouracil-based combination chemotherapy regimens in anticancer therapy

Anti-Cancer Drugs

Volumn 12, Issue 6, 2001, Pages 489-497

  Caponigro, Francesco ^a   Avallone, Antonio ^a   Budillon, Alfredo ^a   Comella, Pasquale ^a   Comella, Giuseppe ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

5 Fluorouracil; Chemotherapy; Oxaliplatin; Raltitrexed

Indexed keywords

FLUOROURACIL; FOLINIC ACID; OXALIPLATIN; RALTITREXED;

ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CLINICAL TRIAL; COLORECTAL CANCER; DIARRHEA; DOSE RESPONSE; DRUG EFFECT; DRUG POTENTIATION; DRUG TOLERANCE; HEAD AND NECK CANCER; HUMAN; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; REVIEW; TREATMENT PLANNING;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL TRIALS; COLORECTAL NEOPLASMS; FLUOROURACIL; HEAD AND NECK NEOPLASMS; HUMANS; LEUCOVORIN; NEOPLASM METASTASIS; NEOPLASMS; ORGANOPLATINUM COMPOUNDS; QUINAZOLINES; RECTAL NEOPLASMS; THIOPHENES;

EID: 0034914634     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-200107000-00001     Document Type: Review

References (36)

1. ICI D1694, a quinazoline antifolate thymidylate synthase inhibitor that is a potent inhibitor of L1210 tumor cell growth in vitro and in vivo: A new agent for clinical study
2. Pretreatment of colon carcinoma cells with Tomudex enhances 5-fluorouracil cytotoxicity
3. The effect of Tomudex on dihydropyrimidine activity
4. Phase I trial of sequential raltitrexed (Tomudex) followed by 5-FU in patients with advanced colorectal cancer
5. Extended phase I study of raltitrexed and infusional 5-FU in patients with metastatic colorectal cancer
6. Phase I and pharmacokinetic study of Tomudex combined with 5-fluorouracil plus levofolinic acid in advanced head and neck and colorectal cancer
7. Biweekly irinotecan or raltitrexed plus 6S-leucovorin and bolus 5-fluorouracil in advanced colorectal carcinoma. A Southern Italy Cooperative Oncology Group phase II/III randomized trial
8. Cisplatin, raltitrexed, levofolinic acid and 5-fluorouracil in locally advanced or metastatic squamous cell carcinoma of the head and neck: A phase I-II trial of the Southern Italy Cooperative Oncology Group (SICOG)
9. Oxaliplatin and raltitrexed combined with leucovorin-modulated 5-fluorouracil i.v. bolus every two weeks: A dose finding study in advanced previously treated colorectal carcinoma
10. Phase I study of mitoxantrone, raltitrexed, levofolinic acid and 5-fluorouracil in advanced solid tumors
11. In vitro cytotoxicity of Tomudex in combination with 5-fluorouracil and levofolinic acid in head and neck and colon cancer cell lines
12. Autoregulation of 5-fluorouracil metabolism
13. Characterisation of dihydropyrimidine dehydrogenase in human colorectal tumors
14. Comparison of plasma and tissue levels of ZD 1694 (Tomudex), a highly polyglutamable quinazoline thymidilate synthase inhibitor, in preclinical models
15. Overview of combined modality therapies for head and neck cancer
16. Relationships between resistance to cisplatin and antifolates in sensitive and resistant tumour cell lines
17. A phase I/II study of tomudex and cisplatin in the treatment of patients with locally advanced or metastatic head and neck cancer
18. Phase I dose escalating study of Tomudex and Cisplatin in metastatic non-small cell lung cancer: Preliminary results
19. A phase II trial of cisplatin, methotrexate, levofolinic acid, and 5-fluorouracil in the treatment of patients with locally advanced or metastatic squamous cell carcinoma of the head and neck
20. Phase II trial of oxaliplatin as first-line chemotherapy in metastatic colorectal cancer patients
21. Oxaliplatin as single agent in previously untreated colorectal carcinoma patients: A phase II multicentric study
22. Two consecutive phase II study of oxaliplatin (L-OHP) for the treatment of patients with advanced colorectal carcinoma who were resistant to previous treatment with fluoropyrimidines
23. Synergistic interaction between oxaliplatin (L-OXP) and 5-fluorouracil (5-FU)
24. Phase I, dose-finding, and pharmacokinetic study of raltitrexed combined with oxaliplatin in patients with advanced cancer
25. Raltitrexed (Tomudex) plus doxorubicin (DOX) in patients with advanced cancer: Results of a phase I dose escalation study
26. A dose finding study of raltitrexed (Tomudex) with cisplatin and epirubicin in advanced gastro-oesophasgeal adenocarcinoma
27. Randomized clinical trial comparing mitoxantrone with doxorubicin in previously treated patients with metastatic breast cancer
28. Mature results from three large controlled studies with raltitrexed (Tomudex)
29. Clinical and pharmacokinetic phase I study of multitargeted antifolate (LY231514) in combination with cisplatin
30. Clinical activity against malignant mesothelioma in a phase I trial of MTA (LY231514) in combination with carboplatin
31. A phase I study of the multitargeted antifolate ALIMTA in combination with oxaliplatin (LOHP) in metastatic colid tumors
32. Organ preservation in rectal cancer
33. Interaction of Tomudex with radiation in vitro and in vivo
34. Raltitrexed ("Tomudex") and radiotherapy can be combined as postoperative treatment for rectal cancer
35. Chemoradiation with raltitrexed ("Tomudex") and concomitant preoperative radiotherapy has potential in the treatment of stage II/III resectable rectal cancer
36. "Tomudex" (raltitrexed) plus radiotherapy as post-operative treatment or palliative treatment for patients with rectal cancer: Phase I studies